Oxidative Medicine and Cellular Longevity

Research Article

The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index

Table 3

Lipid profile, oxidized low-density lipoprotein (oxLDL), paraoxonase (PON) 1 activity, C-reactive protein (CRP), adipokines, and fractions and subfractions of lipoproteins for end-stage renal disease (ESRD) patients on chronic dialysis, according to body mas index (BMI) groups.


	kg/m²()	–24.9 kg/m² ()	–29.9 kg/m² ()	kg/m² ()

Biochemical data
TC (mg/dl)
HDLc (mg/dl)	54.4 (53.1–83.1)	49.4^a, (41.8–59.8)	44.5^aa (36.3–54.1)^b,	40.9^aaa (34.8–48.7)^bbb
LDLc (mg/dl)	62 (79–94)	77 (64–108)	79 (59–101)	80 (63–103)
TG (mg/dl)	111.5 (74.8–140.0)	116.0 (83.5–161.0)	134.5 (99.0–194.0)^b,	156.0^a, (114.0–237.0)^bb,
TC/HDLc	2.96 (2.17–3.17)	3.13 (2.52–3.74)	3.24 (2.76–4.21)	3.96^a (3.03-4.26)^bb,
LDLc/HDLc	1.39 (0.87–1.68)	1.71 (1.18–2.10)	1.71 (1.30–2.40)	2.01^a, (1.44–2.42)^b,
oxLDL (U/l)	45.8 (29.2–52.2)	44.6 (36.1–55.8)	49.6 (35.3–62.9)	50.0 (41.5–63.7)^b,
oxLDL/LDLc (U/mg)	0.052 (0.045–0.065)	0.047 (0.054–0.066)	0.052 (0.060–0.075)^b,	0.064 (0.051–0.076)^b,
PON1 (nmol of p-nitrophenol/ml/min)	379 (339–464)	393 (362–459)	423 (353–488)	399 (368–465)
PON1/HDLc	6.56 (4.11–8.79)	8.31 (6.38–10.35)	9.54^a, (7.69–11.20)^b,	9.99^aa, (8.68–12.13)^bb
CRP (mg/dl)	0.44 (0.21–2.08)	0.32 (0.12–0.71)	0.36 (0.18–0.74)	0.42 (0.19–0.75)
Adiponectin (ug/ml)	28.65 (20.93–35.69)	16.24^aa (9.73–23.56)	11.48^aaa (7.25–16.20)^bb,	8.23^aaa (5.43–12.78)^bbb
Leptin (ng/ml)	3.40 (0.70–7.37)	6.50 (2.44–17.36)	17.42^aa, (6.96–49.19)^bbb,	43.08^aaa (20.31–97.09)^bbb,ccc
Lipoprotein fractions/subfractions
VLDL (%)				^bbb
MID-C (%)
MID-B (%)	6.9 (5.6–7.5)	7.8 (6.3–8.8)	7.9^a, (7.0–9.6)	7.7^a, (7.0-9.5)
MID-A (%)	6.2 (4.1–7.5)	6.6 (5.3–8.4)	6.9 (5.6–8.8)	6.9 (5.2–8.3)
LDL 1 (%)	12.3 (9.4–13.9)	13.4 (11.2–16.2)	13.0 (10.3–15.7)	12.8 (10.9–15.2)
LDL 2 (%)	7.2 (6.4–11.0)	8.2 (5.4–11.1)	7.8 (5.4–10.0)	8.4 (5.8–11.7)
LDL 3-7 (%)	1.2 (0.9–1.6)	0.0 (0.0–1.8)	0.7 (0.0–1.8)	0.8 (0.0–2.0)
HDL (%)	31.1 (29.6–38.2)	27.4 (24.2–32.3)	26.7^a (22.7–29.9)^bb	25.0^aa (21.8–27.6)
LDL size	270 (269–270)	271 (268–272)	270 (268–273)	270 (267–272)
HDL subfractions
Large HDL (%)	43.8 (40.5–47.7)	40.7 (30.0–49.3)	36.6^a, (26.6–43.2)^b,	28.6^a, (24.7–37.9)^{bbb; c,}
Intermediate HDL (%)	43.3 (39.8-45.3)	44.3 (39.8–48.2)	46.3 (40.7–50.0)	48.5^a, (44.5–50.5)^bb,
Small HDL (%)	13.3 (11.0–16.7)	14.1 (10.6–21.0)	17.4 (13.5–22.4)^b,	21.2^a, (15.9–27.3)^{bbb; c,}

TC: total cholesterol; HDLc: high-density lipoprotein cholesterol; TG: triglycerides; VLDL: very-low-density lipoprotein; MID: midbands (these comprise intermediate-density lipoprotein (IDL)); LDL 3–7 corresponds to small LDL subfractions. Values are presented as median (interquartile range) or as deviation (SD); ^a, ^aa, and ^aaa vs. ESRD patients with kg/m²; ^b, ^bb, and ^bbb vs. ESRD patients with BMI 18.5–24.9 kg/m²; ^c, ^cc, and ^ccc vs. ESRD patients with BMI 24.9–29.9 kg/m²; loss of significance after statistical adjustment for diabetes.